The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Chomps beef and turkey sticks pulled from shelves in multi-state recall after metal fragments discovered; manufacturer urges consumers to check lot codes and return affected products for refund.
Late reporting was concentrated among a small number of manufacturers, with 3 manufacturers and 13 devices accounting for 54.8% of all late reports between 2019 and 2022.
Maternal age distribution shifts dramatically as overall birth rates continue a 30-year decline, with women younger than 30 now accounting for less than half of all births, and an increase of older mothers.